Solaxa Announces Phase 3 Clinical Trial for Spinocerebellar Ataxia Type 27B
Solaxa Announces Phase 3 Clinical Trial for Spinocerebellar Ataxia Type 27B Bethesda, MD — March 28, 2025 – Solaxa Inc., […]
Press
Press
Press
Solaxa Inc. Announces FDA Clearance of IND Application for SLX-100
Solaxa Inc. Announces FDA Clearance of IND Application for SLX-100 Bethesda, MD; January 6, 2024 – Solaxa Inc. announces today
Press
Solaxa Inc. Collaborates with National Ataxia Foundation
Solaxa Inc. Collaborates with National Ataxia Foundation Bethesda, MD and Minneapolis, MN; September 25, 2024 – On International Ataxia Awareness
Solaxa Inc. Appoints Kerry Clem as Chief Commercial Officer
Solaxa Inc. Appoints Kerry Clem as Chief Commercial Officer Bethesda, MD; August 19, 2024 – Solaxa Inc. announces that Kerry
U.S. Food and Drug Administration Grants Orphan Drug Designation to Solaxa Inc.
U.S. Food and Drug Administration Grants Orphan Drug Designation to Solaxa Inc. Bethesda, MD; July 26, 2024 – Solaxa Inc.
Solaxa Inc. Appoints Amy Chappel, MD, FAAN as Chief Medical Officer
Solaxa Inc. Appoints Amy Chappel, MD, FAAN as Chief Medical Officer Bethesda, MD; January 1, 2024 – Solaxa Inc. announces
Solaxa Inc. Begins Operations as a Public Benefit Corporation
Solaxa Inc. Begins Operations as a Public Benefit Corporation Bethesda, MD; February 24, 2022 – Solaxa Inc. today announces its